Spruce Biosciences Confirms Q4 2026 BLA Submission For TA-ERT Following Positive FDA Meetings

Spruce Biosciences (SPRB) said it remains on track to submit a BLA for TA-ERT for Sanfilippo Syndrome Type B in Q4 2026 after positive pre-BLA meetings with the FDA.